Metropolitan Life Insurance Co. NY reduced its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 22.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 40,866 shares of the medical instruments supplierâs stock after selling 11,900 shares during the quarter. Metropolitan Life Insurance Co. NYâs holdings in Becton Dickinson and were worth $9,790,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of Becton Dickinson and by 13.7% during the 2nd quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplierâs stock worth $4,069,559,000 after buying an additional 2,049,874 shares during the last quarter. Charles Schwab Investment Advisory Inc. bought a new stake in shares of Becton Dickinson and during the 2nd quarter worth $291,167,000. Vontobel Asset Management Inc. lifted its position in shares of Becton Dickinson and by 823.0% during the 2nd quarter. Vontobel Asset Management Inc. now owns 1,013,953 shares of the medical instruments supplierâs stock worth $250,205,000 after buying an additional 904,097 shares during the last quarter. Sustainable Growth Advisers LP bought a new stake in shares of Becton Dickinson and during the 1st quarter worth $166,282,000. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of Becton Dickinson and during the 1st quarter worth $87,368,000. 92.51% of the stock is currently owned by institutional investors.
Several analysts recently weighed in on the company. Wells Fargo & Co upped their price objective on Becton Dickinson and from $275.00 to $290.00 and gave the stock an âoutperformâ rating in a research report on Thursday, September 6th. They noted that the move was a valuation call. Royal Bank of Canada reiterated a âholdâ rating and issued a $248.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. Citigroup increased their target price on Becton Dickinson and from $274.00 to $283.00 and gave the company a âbuyâ rating in a research report on Wednesday, August 8th. JPMorgan Chase & Co. upgraded Becton Dickinson and from a âneutralâ rating to an âoverweightâ rating and set a $175.00 target price for the company in a research report on Thursday, June 21st. Finally, KeyCorp reiterated a âbuyâ rating and issued a $264.00 target price on shares of Becton Dickinson and in a research report on Friday, August 3rd. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of âBuyâ and an average price target of $253.79.Shares of BDX opened at $253.77 on Friday. Becton Dickinson and Co has a 1 year low of $195.72 and a 1 year high of $265.87. The stock has a market cap of $69.83 billion, a PE ratio of 26.60, a P/E/G ratio of 1.78 and a beta of 1.11. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 EPS for the quarter, topping the consensus estimate of $2.86 by $0.05. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The business had revenue of $4.28 billion during the quarter, compared to analystsâ expectations of $4.25 billion. During the same quarter last year, the firm posted $2.46 earnings per share. The firmâs revenue was up 41.0% on a year-over-year basis. On average, research analysts anticipate that Becton Dickinson and Co will post 11.01 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 28th. Investors of record on Friday, September 7th were paid a dividend of $0.75 per share. The ex-dividend date of this dividend was Thursday, September 6th. This represents a $3.00 annualized dividend and a yield of 1.18%. Becton Dickinson andâs dividend payout ratio is currently 31.65%.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
See Also: What is a Stop Order?
Receive News & Ratings for Becton Dickinson and Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Becton Dickinson and and related companies with MarketBeat.com’s FREE daily email newsletter.